和誉医药口服小分子KRAS G12D抑制剂ABSK141完成首例患者给药
KRAS是人类癌症中最常见的致癌驱动基因之一，其中G12D为最主要的突变亚型，广泛...
Sintilimab plus anlotinib in later-line treatment of advanced KRAS-mutant NSCLC: a multicenter, retrospective case series
BackgroundPatients with advanced KRAS-mutant non-small cell lung cancer (NSCLC) face a paucity of effective later-line therapies. While combining PD-1 inhibi Abstract Background: Patients with advanced KRAS-mutant non-small cell lung cancer (NSCLC) face a paucity of effective later-line therapies. While combining...
2026 TTLC Symposia on RAS(ON) Inhibition in KRAS-Mutated NSCLC – IASLC
2026 TTLC Symposia on RAS(ON) Inhibition in KRAS-Mutated NSCLC – IASLC RAS(ON) Inhibition: On the Path to Overcoming Therapeutic Resistance and Targeting More Variants in KRAS-Mutated NSCLC. Join this engaging CME symposium exploring the evolving treatment landscape of KRAS-mutated NSCLC....
2026 TTLC Symposia on RAS(ON) Inhibition in KRAS-Mutated NSCLC - IASLC
2026 TTLC Symposia on RAS(ON) Inhibition in KRAS-Mutated NSCLC - IASLC / Alex Spira, cancer, International Association for the Study of Lung Cancer, Kathryn Alex Spira and Kathryn C. Arbour 2026 TTLC Symposia on RAS(ON) Inhibition in KRAS-Mutated NSCLC –...
Lung adenocarcinoma with KRAS-Q61H: clinicopathologic features, diagnostics, and the evolving treatment landscape
KRAS is one of the most frequently mutated oncogenes in lung adenocarcinoma (LUAD), with the KRAS-Q61H mutation representing a rare but biologically distinct Introduction Lung adenocarcinoma is the most common histologic subtype of non-small cell lung cancer (NSCLC) and is...